ValuEngine Upgrades Synthetic Biologics Inc (SYN) to “Sell”
Synthetic Biologics Inc (NYSEMKT:SYN) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Friday.
Several other equities research analysts also recently commented on SYN. Zacks Investment Research downgraded Synthetic Biologics from a “hold” rating to a “sell” rating in a report on Thursday, May 4th. William Blair reiterated an “outperform” rating and set a $5.00 target price on shares of Synthetic Biologics in a report on Monday, May 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Synthetic Biologics presently has a consensus rating of “Buy” and an average price target of $4.51.
Shares of Synthetic Biologics (NYSEMKT SYN) traded up 8.8844% during trading on Friday, hitting $0.6422. The stock had a trading volume of 2,052,242 shares. Synthetic Biologics has a one year low of $0.41 and a one year high of $1.90. The stock’s 50-day moving average price is $0.54 and its 200-day moving average price is $0.62. The company’s market cap is $82.36 million.
Synthetic Biologics (NYSEMKT:SYN) last announced its earnings results on Thursday, August 3rd. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.03. On average, equities research analysts forecast that Synthetic Biologics will post ($0.17) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/18/valuengine-upgrades-synthetic-biologics-inc-syn-to-sell.html.
A number of large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its stake in Synthetic Biologics by 8,102.7% in the second quarter. Goldman Sachs Group Inc. now owns 1,129,108 shares of the company’s stock valued at $639,000 after buying an additional 1,115,343 shares in the last quarter. Norges Bank acquired a new stake in Synthetic Biologics during the fourth quarter valued at about $356,000. LMR Partners LLP acquired a new stake in Synthetic Biologics during the second quarter valued at about $194,000. Susquehanna International Group LLP increased its stake in Synthetic Biologics by 76.4% in the second quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock valued at $107,000 after buying an additional 82,030 shares in the last quarter. Finally, Creative Planning increased its stake in Synthetic Biologics by 65.4% in the second quarter. Creative Planning now owns 177,000 shares of the company’s stock valued at $100,000 after buying an additional 70,000 shares in the last quarter.
About Synthetic Biologics
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.